✦ LIBER ✦

559 COST-EFFECTIVENESS SIMULATION ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE (TENOFOVIR) IN HBEAG NEGATIVE (-) PATIENTS WITH CHRONIC HEPATITIS-B (CHB) IN ITALY AND FRANCE

✍ Scribed by B. Deniz; F. Everhard

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

558 COST-EFFECTIVENESS SIMULATION ANALYS

✍ B. Deniz; M. Buti; M. Brosa; M.A. Casado; M. Rueda; F. Everhard; R. Esteban 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Cost Effectiveness Analysis Of Tenofovir

✍ Soto, H.; Botello, B.S.; Pizarro, M.; Rizzoli, A.; Gozález, L.A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Randomized Comparison of Tenofovir Disop

✍ Fung, Scott; Kwan, Peter; Fabri, Milotka; Horban, Andrzej; Pelemis, Mijomir; Han 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 639 KB

925 SAFETY AND TOLERABILITY OF 96 WEEKS

✍ P. Marcellin; E.J. Heathcote; I. Jacobson; P. Mathurin; E. Gane; P. Buggisch; P. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 161 KB

W1814 Safety and Tolerability of 96 Week

✍ Jacobson, Ira M.; Marcellin, Patrick; Heathcote, Jenny; Mathurin, Philippe; Gane 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Cost–Utility Analysis of Tenofovir Disop

✍ Helen Dakin; Anthony Bentley; Geoff Dusheiko 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 317 KB